Brought to you by 
PTC Therapeutics sells $250mm in convertible debt financing
20 Sep 2019
Executive Summary
Rare disease-focused PTC Therapeutics Inc. sold $250mm aggregate principal amount of its 1.5% convertible senior notes due 2026 to qualified institutional buyers. The notes convert at an initial rate of 19.0404 shares of common stock per $1k principal amount, or $52.52 per share (its stock is currently averaging $43.07).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PTC Therapeutics sells $250mm in convertible debt financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice